ERIC 2020 | Taking MRD from trials to the clinic
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses how the diagnostics and procedures that are used in trials but not yet implemented in the clinic, need to be debated. The prime example is measurable residual disease (MRD). Prof. Kater gives an overview of the diagnostic aspects and clinical interpretation of MRD. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Transcript (edited for clarity)
Also happening now in CLL more and more is that we do diagnostics and procedures in trials that have not been implemented yet in the clinic. And therefore a deviation occurs between what you’re do in real life and what you do if patients enter a trial. And one of those prime examples is MRD, which has become a very well-known and respected, maybe surrogate, maybe a real but a primary endpoint of clinical studies...
Also happening now in CLL more and more is that we do diagnostics and procedures in trials that have not been implemented yet in the clinic. And therefore a deviation occurs between what you’re do in real life and what you do if patients enter a trial. And one of those prime examples is MRD, which has become a very well-known and respected, maybe surrogate, maybe a real but a primary endpoint of clinical studies. And I think we need to discuss with each other how to interpret those data and specifically also the technicalities of it. So what does it mean on the clinical perspective? Is it already time to take it to the clinic for clinical decision-making and how should we do that? That’s something that we need to debate with each other. And also the technical challenges that we have in these measurements is something that we have to realize most as lab people, but specifically as clinicians, we need to know the pitfalls of this technique and also how to read it and perhaps how to improve it.
Read more...
